@article {Casper2020.10.22.20217885, author = {M Casper and MC Reichert and J Rissland and S Smola and F Lammert and M Krawczyk}, title = {Pre-endoscopy SARS-CoV-2 testing strategy during COVID-19 pandemic: The care must go on}, elocation-id = {2020.10.22.20217885}, year = {2020}, doi = {10.1101/2020.10.22.20217885}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background In response to the COVID-19 pandemic, endoscopic societies have recommended reduction of endoscopic procedures. In particular non-urgent endoscopies should be postponed. However, this might lead to unnecessary delay in diagnosing gastrointestinal conditions.Methods Retrospectively we analysed the gastrointestinal endoscopies performed at the Central Endoscopy Unit of Saarland University Medical Center during seven weeks from 23 March to 10 May 2020 and present our real-world single-center experience with an individualized rtPCR-based pre-endoscopy SARS-CoV-2 testing ({\textquotedblleft}PECo{\textquotedblright}) strategy.Results Altogether 359 gastrointestinal endoscopies were performed. The PECo strategy enabled us to conservatively handle endoscopy program reduction (44\% reduction as compared 2019). The results of COVID-19 rtPCR from nasopharyngeal swabs were available in 89\% of patients prior to endoscopies. Apart from six patients with known COVID-19, all other tested patients were negative. The frequencies of endoscopic therapies and clinically significant findings did not differ between patients with or without SARS-CoV-2 tests.Conclusion A reasonable reduction of the endoscopy program in the setting of structured SARS-CoV-2 testing is feasible and safe. The PECo strategy allows continuation of endoscopic procedures in a region with intermediate frequency of COVID-19 when hospital capacities are not overwhelmed by the pandemic. Thus, the study might help to develop new strategies during future waves of COVID-19 or local outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding source relevant to this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of Aerztekammer des Saarlandes (Saarbruecken, Germany; $\#$254/20). A waiver was obtained for the consent to participate in the study. The study was performed in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analysed during the current study are available from the corresponding author on reasonable request.rtPCRReverse transcriptase polymerase chain reactionERCPEndoscopic retrograde cholangiopancreatographyEUSEndoscopic ultrasoundPECoPre-endoscopy SARS-CoV-2 testingPEGPercutaneous endoscopic gastrostomyPPEPersonal protective equipment}, URL = {https://www.medrxiv.org/content/early/2020/10/27/2020.10.22.20217885}, eprint = {https://www.medrxiv.org/content/early/2020/10/27/2020.10.22.20217885.full.pdf}, journal = {medRxiv} }